文献速递眼底病与葡萄膜炎

活动性葡萄膜炎合并中心性浆液性脉络膜视网膜病变的发病率、管理与转归

Incidence, Management, and Outcomes of Eyes with Comorbid Active Uveitis and Central Serous Chorioretinopathy.
PubMed 文献 · Retina · 2025-04-02

该回顾性病历回顾研究在8年期间4034例葡萄膜炎患者中识别出20例(0.5%)合并活动性葡萄膜炎与中心性浆液性脉络膜视网膜病变(CSCR),随访中位34个月。按诊断顺序分层:队列1中4眼(3例)先诊活动性葡萄膜炎、后于糖皮质激素起始后中位65天发生活动性CSCR,停药后中位104天全部消退;队列2中21眼(17例)先有无活动性CSCR、后诊活动性葡萄膜炎。最终随访时所有患者葡萄膜炎与CSCR均无活动。

要点

  • 4034例葡萄膜炎患者中20例(0.5%)合并活动性葡萄膜炎与CSCR,随访中位34个月。
  • 队列1中4眼(3例)在糖皮质激素起始后中位65天发生活动性CSCR,停药后中位104天全部消退。
  • 队列2中15眼(12例)接受糖皮质激素治疗,其中9眼(8例)发生活动性CSCR,6眼(5例)停药后CSCR持续需靶向治疗。

核心结论

  • CSCR与葡萄膜炎之间存在复杂关系,通过审慎使用糖皮质激素、非甾体免疫抑制及针对持续性CSCR的靶向治疗,有可能控制两种疾病。

研究设计与样本

  • 回顾性病历回顾,纳入8年研究期间诊断为葡萄膜炎的4034例患者,其中20例(0.5%)合并活动性葡萄膜炎与CSCR,随访中位34个月。

主要发现

  • 队列1中4眼(3例)先诊活动性葡萄膜炎、后于糖皮质激素起始后中位65天发生活动性CSCR,停药后中位104天全部消退。
  • 队列1中3眼(2例)在糖皮质激素撤退时出现炎症加重,需糖皮质激素节约型免疫抑制。
  • 队列2中21眼(17例)先有无活动性CSCR、后诊活动性葡萄膜炎;15眼(12例)接受糖皮质激素治疗,其中9眼(8例)发生活动性CSCR。
  • 队列2中6眼(5例)在糖皮质激素撤退后CSCR持续,需针对CSCR的靶向治疗;另6眼(5例)观察或局部NSAIDs治疗,葡萄膜炎消退。
  • 最终随访时所有患者葡萄膜炎与CSCR均无活动。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the incidence, management, and outcomes of eyes with active uveitis and central serous chorioretinopathy (CSCR). METHODS: Retrospective chart review. RESULTS: Of 4,034 patients diagnosed with uveitis during the 8-year study period, 20 (0.5%) had comorbid active uveitis and CSCR, followed for a median of 34 months. Patients were stratified based on diagnoses sequence. In Cohort 1, 4 eyes (3 patients) initially diagnosed with active uveitis and later developed active CSCR at a median of 65 days following corticosteroid initiation, with resolution of CSCR occurring in all eyes at a median of 104 days after withdrawing corticosteroids. Three eyes (2 patients) developed worsening inflammation upon corticosteroid withdrawal requiring corticosteroid-sparing immunosuppression. In Cohort 2, 21 eyes (17 patients) with inactive CSCR were later diagnosed with active uveitis. Fifteen eyes (12 patients) were treated with corticosteroids and 9 eyes (8 patients) developed active CSCR. The CSCR persisted after corticosteroid withdrawal in 6 eyes (5 patients) necessitating targeted therapy for CSCR. The other 6 eyes (5 patients) of Cohort 2 were observed or treated with topical NSAIDS with resolution of uveitis. All patients had inactive uveitis and CSCR at final follow-up. CONCLUSIONS: A complex relationship exists between CSCR and uveitis. Control of both diseases is possible through judicious use of corticosteroids, non-steroidal immunosuppression, and therapies targeted at persistent CSCR.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Nguyen MK, Momenaei B, Yu J, et al. Incidence, Management, and Outcomes of Eyes with Comorbid Active Uveitis and Central Serous Chorioretinopathy. Retina. 2025. PMID: 40184582. doi:10.1097/IAE.0000000000004478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。